Navigation Links
Trillium secures additional financing on the strength of lead program and proprietary position around the CD200 immunoregulatory pathway
Date:9/18/2008

TORONTO, Sept. 18 /PRNewswire/ - Trillium Therapeutics Inc., a privately-held biopharmaceutical company specializing in the development of innovative therapies for the treatment of immune-mediated disorders, announced today that it has secured $12 million in new financing from its existing investors, VenGrowth Private Equity Partners, BDC Capital and Canadian Medical Discoveries Fund (CMDF).

"We are fortunate to have the continued support of some of Canada's premier venture capital investors, especially under these trying market conditions," commented Trillium CEO Dr. Niclas Stiernholm. "These funds will allow us to advance several programs into clinical development, elevating the company to a new level and opening up new strategic possibilities in 2009."

Trillium will use the majority of the proceeds to fund clinical trials of its lead product candidate, TTI-1612, a recombinant growth factor under parallel development for the prevention of necrotizing enterocolitis and the treatment of interstitial cystitis. TTI-1612 is on track to begin clinical testing by the end of 2008, and two additional trials are projected to commence in 2009. The company's two preclinical programs, a CD200-specific monoclonal antibody for the treatment of cancer, and a CD200Fc fusion protein for the treatment of autoimmune and inflammatory diseases, continue to hold promise and to generate strong scientific and commercial interest.

"Our continued support for Trillium is driven by the quality of the lead program TTI-1612, the strong patent position around the exciting new immunoregulatory target CD200, and management's proven ability to execute partnerships," added Dr. Luc Marengere, of VenGrowth Private Equity Partners, Trillium's largest investor.

About Trillium: Trillium Therapeutics Inc. is a private biopharmaceutical company specializing in innovative therapies of immune-mediated conditions, such as autoimmune and inflammatory disorders, as well as cancer. The company's lead program, a recombinant growth factor, is being developed for the prevention of necrotizing enterocolitis and the treatment of interstitial cystitis. Trillium has two preclinical programs targeting the CD200 immunoregulatory axis; a CD200-specific monoclonal antibody for the treatment of cancer and a CD200Fc fusion protein for the treatment of autoimmune and inflammatory diseases. The company has a broad network of external academic and industry R&D collaborations, including several license agreements with major US biotechnology companies.


'/>"/>
SOURCE Trillium Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Althea Technologies Secures $12 M Credit Line to Continue Facility Growth and Expansion
2. Progenitor Cell Therapy Secures Industry Accreditation
3. BIOCOM Institute Secures Non-Profit Designation and Funding
4. Cara Therapeutics Secures $12.3 Million in Series C Extension Financing
5. OMTEC 2008 Boasts Record Attendance and Secures Premier Position as Must-attend for Orthopaedic Companies
6. Genta Secures Up to $40 Million Convertible Financing Facility to Fund Key Programs
7. Novasys Medical Secures $49.5 Million in Series D Financing to Expand Commercialization of Its Renessa(R) Treatment for Incontinence in Women
8. Veran Medical Technologies Secures $4.75M in First Institutional Funding
9. Northwest Secures US$4.0 Million in Debt Financing
10. D-Pharm Secures Funding From Israels Chief Scientists Office
11. Aerovance Secures $20 Million in Debt Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... A ... pregnancy rates in frozen and fresh in vitro fertilization (IVF) transfer ... age to IVF success. , After comparing the results from the fresh and ...
(Date:10/10/2017)... ... 2017 , ... For the second time in three years, ... Award. Representatives of the FirstHand program travelled to Washington, D.C. Tuesday, October 10th, ... mission is to change the trajectory of STEM education in America by dramatically ...
(Date:10/10/2017)... ... October 10, 2017 , ... USDM Life Sciences , ... life sciences and healthcare industries, announces a presentation by Subbu Viswanathan and Jennifer ... “Automating GxP Validation for Agile Cloud Platforms,” will present a revolutionary approach to ...
(Date:10/9/2017)... (PRWEB) , ... October 09, 2017 , ... At its ... Dr. Christopher Stubbs, a professor in Harvard University’s Departments of Physics and Astronomy, has ... was a member of the winning team for the 2015 Breakthrough Prize in Fundamental ...
Breaking Biology Technology:
(Date:4/19/2017)... New York , April 19, 2017 ... competitive, as its vendor landscape is marked by the ... the market is however held by five major players ... Safran. Together these companies accounted for nearly 61% of ... of the leading companies in the global military biometrics ...
(Date:4/13/2017)... April 13, 2017 UBM,s Advanced Design and ... will feature emerging and evolving technology through its 3D ... will run alongside the expo portion of the event ... and demonstrations focused on trending topics within 3D printing ... and manufacturing event will take place June 13-15, 2017 at ...
(Date:4/11/2017)... 2017 Research and Markets has announced the ... to their offering. ... eye tracking market to grow at a CAGR of 30.37% during ... Market 2017-2021, has been prepared based on an in-depth market analysis ... and its growth prospects over the coming years. The report also ...
Breaking Biology News(10 mins):